PMID- 34508066
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210925
IS  - 2157-9024 (Print)
IS  - 2157-9024 (Electronic)
IS  - 2157-9024 (Linking)
VI  - 10
IP  - 9
DP  - 2021 Sep 10
TI  - Tripartite motif-containing 3 (TRIM3) enhances ER signaling and confers tamoxifen 
      resistance in breast cancer.
PG  - 60
LID - 10.1038/s41389-021-00350-x [doi]
LID - 60
AB  - Tamoxifen resistance remains a clinical problem in estrogen receptor 
      (ER)-positive breast cancer. SUMOylation of ERalpha enhances ERalpha-induced 
      transcription activity. Tripartite motif-containing (TRIM) proteins are a new 
      class of SUMO E3 ligases, which regulate the SUMOylation of proteins. However, 
      the precise molecular mechanism and function of TRIM3 in SUMOylation and the 
      response to tamoxifen remain unclear. In the present study, we observed that 
      TRIM3 was dramatically overexpressed in breast cancer, which correlated with 
      tamoxifen resistance. Furthermore, TRIM3 overexpression significantly correlated 
      with poor survival of patients with ER(+) breast cancer treated with tamoxifen. 
      TRIM3 overexpression conferred cell survival and tumorigenesis, whereas knocking 
      down of TRIM3 reduced these capabilities. Moreover, TRIM3, as a ubiquitin carrier 
      protein 9 (UBC9) binding protein, promoted SUMO modification of estrogen receptor 
      1 (ESR1) and activated the ER pathway. Silencing UBC9 abolished the function of 
      TRIM3 in regulating tamoxifen resistance. These results suggest TRIM3 as a novel 
      biomarker for breast cancer therapy, indicating that inhibiting TRIM3 combined 
      with tamoxifen might provide a potential treatment for breast cancer.
CI  - (c) 2021. The Author(s).
FAU - Ye, Runyi
AU  - Ye R
AUID- ORCID: 0000-0002-7652-8034
AD  - Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, Guangdong, China. yeryi@mail.sysu.edu.cn.
FAU - AiErken, NiJiati
AU  - AiErken N
AD  - Department of Breast and Thyroid Surgery, The Seventh Affiliated Hospital, Sun 
      Yat-sen University, ShenZhen, 518107, China.
FAU - Kuang, Xiaying
AU  - Kuang X
AD  - Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, Guangdong, China.
FAU - Zeng, Huijuan
AU  - Zeng H
AD  - Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, Guangdong, China.
FAU - Shao, Nan
AU  - Shao N
AD  - Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, Guangdong, China.
FAU - Lin, Ying
AU  - Lin Y
AD  - Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, Guangdong, China.
FAU - Liu, Pian
AU  - Liu P
AUID- ORCID: 0000-0001-5780-3902
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, 430022, China. liupianamazing@126.com.
FAU - Wang, Shenming
AU  - Wang S
AUID- ORCID: 0000-0003-1058-484X
AD  - Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Sun 
      Yat-sen University, Guangzhou, Guangdong, China. wshenm@163.com.
LA  - eng
GR  - 81772800/National Natural Science Foundation of China (National Science 
      Foundation of China)/
PT  - Journal Article
DEP - 20210910
PL  - United States
TA  - Oncogenesis
JT  - Oncogenesis
JID - 101580004
PMC - PMC8433133
COIS- The authors declare no competing interests.
EDAT- 2021/09/12 06:00
MHDA- 2021/09/12 06:01
PMCR- 2021/09/10
CRDT- 2021/09/11 05:34
PHST- 2021/03/10 00:00 [received]
PHST- 2021/08/23 00:00 [accepted]
PHST- 2021/08/02 00:00 [revised]
PHST- 2021/09/11 05:34 [entrez]
PHST- 2021/09/12 06:00 [pubmed]
PHST- 2021/09/12 06:01 [medline]
PHST- 2021/09/10 00:00 [pmc-release]
AID - 10.1038/s41389-021-00350-x [pii]
AID - 350 [pii]
AID - 10.1038/s41389-021-00350-x [doi]
PST - epublish
SO  - Oncogenesis. 2021 Sep 10;10(9):60. doi: 10.1038/s41389-021-00350-x.